Current Report Filing (8-k)
August 06 2020 - 4:47PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 5, 2020
IMAC Holdings, Inc.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
Delaware
|
001-38797
|
83-0784691
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
1605 Westgate Circle, Brentwood, Tennessee
|
37027
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s Telephone Number, Including
Area Code: (844) 266-4622
|
(Former Name or Former Address, If Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
Common Stock, par value $0.001 per share
|
IMAC
|
The NASDAQ Stock Market LLC
|
Warrants to Purchase Common Stock
|
IMACW
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other
Events.
On August 5, 2020, IMAC Holdings, Inc.
(the “Company”) issued a press release announcing the approval by the United States Food and Drug Administration (the
“FDA”) of the Company’s investigational new drug application, which IMAC submitted in May 2020, for the use of
umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual loss and slowing down
of spontaneous body movement, due to Parkinson’s disease. Pursuant to the FDA’s approval, the Company anticipates beginning
a phase 1 clinical trial of its stem cell treatment within 30 days. A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
Cautionary Note Regarding Forward-Looking
Statements
The information contained
in this Current Report on Form 8-K and the exhibits attached hereto contain “forward-looking” statements within the
meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to the benefits
of the Transaction. The words “intend,” “may,” “should,” “would,” “expect,”
“plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential”
or “continue” or the negative of these terms or other comparable terminology are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words. While the Company believes its plans,
intentions and expectations reflected in those forward-looking statements are reasonable, these plans, intentions or expectations
may not be achieved. The Company’s actual results, performance or achievements could differ materially from those contemplated,
expressed or implied by the forward-looking statements. For information about the factors that could cause such differences, please
refer to the Company’s filings with the U.S. Securities and Exchange Commission. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. The Company assumes no obligation to update any forward-looking statement.
Item 9.01 Financial
Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
August 6, 2020
|
IMAC HOLDINGS, INC.
|
|
|
|
By:
|
/s/ Jeffrey
S. Ervin
|
|
|
Name:
|
Jeffrey S. Ervin
|
|
|
Title:
|
Chief Executive Officer
|
IMAC (NASDAQ:IMAC)
Historical Stock Chart
From Aug 2024 to Sep 2024
IMAC (NASDAQ:IMAC)
Historical Stock Chart
From Sep 2023 to Sep 2024